Q-omics provides the consensus-scored SNHG20 profile across patient tissues and cancer cell-line models. SNHG20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNHG20 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SNHG20 RNA expression shows 20,486 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where SNHG20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG20 survival associations across molecular data types. SNHG20 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG20 RNA expression–survival associations across cancer types. High SNHG20 expression shows unfavorable associations in ACC, LIHC, UVM and KIRC, but favorable associations in BLCA and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNHG20 RNA expression.
This table summarizes SNHG20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG20 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRC, LIHC, BLCA and STAD. The COAD box plot shows higher SNHG20 RNA expression in tumor versus normal tissue (log2 FC = +1.192, t-test p < 0.001).
This table shows molecular features associated with SNHG20 in patient tissues and cancer cell lines. In patient samples, SNHG20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
